In a SOD1-linked ALS context, enhancing m6A levels in adult MNs either via small molecule treatment or scAAV9 delivery delays the onset of MN degeneration and enhances motor function. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.